Brokerages Set Ralliant Corporation (NYSE:RAL) Price Target at $73.00

Shares of Ralliant Corporation (NYSE:RAL) have been given a consensus rating of “Moderate Buy” by the twelve ratings firms that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation, seven have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $73.00.

A number of brokerages have recently issued reports on RAL. Citigroup boosted their price target on shares of Ralliant from $70.00 to $81.00 and gave the stock a “buy” rating in a research report on Monday, July 13th. TD Cowen increased their price objective on shares of Ralliant from $55.00 to $70.00 and gave the stock a “buy” rating in a research report on Wednesday, May 20th. Weiss Ratings reissued a “sell (d)” rating on shares of Ralliant in a research note on Monday, May 4th. Wall Street Zen lowered shares of Ralliant from a “buy” rating to a “hold” rating in a report on Sunday. Finally, Vertical Research lowered shares of Ralliant from a “buy” rating to a “hold” rating and set a $65.00 target price on the stock. in a report on Wednesday, May 27th.

Ralliant Price Performance

Ralliant stock opened at $66.85 on Friday. The stock’s 50 day moving average is $66.98 and its 200 day moving average is $54.16. Ralliant has a one year low of $37.27 and a one year high of $75.41. The firm has a market cap of $7.48 billion and a P/E ratio of -6.11. The company has a debt-to-equity ratio of 0.73, a current ratio of 1.61 and a quick ratio of 1.05.

Ralliant (NYSE:RAL) last released its earnings results on Tuesday, May 12th. The company reported $0.57 earnings per share for the quarter, beating analysts’ consensus estimates of $0.49 by $0.08. Ralliant had a negative net margin of 58.55% and a positive return on equity of 12.49%. The business had revenue of $534.60 million during the quarter. Ralliant’s revenue was up 11.0% on a year-over-year basis. Ralliant has set its FY 2026 guidance at 2.530-2.690 EPS and its Q2 2026 guidance at 0.580-0.640 EPS. As a group, research analysts expect that Ralliant will post 2.64 EPS for the current year.

Ralliant Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, June 23rd. Stockholders of record on Monday, June 8th were given a $0.05 dividend. The ex-dividend date of this dividend was Monday, June 8th. This represents a $0.20 annualized dividend and a dividend yield of 0.3%. Ralliant’s dividend payout ratio (DPR) is -1.83%.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in RAL. Phocas Financial Corp. lifted its stake in Ralliant by 81.2% in the fourth quarter. Phocas Financial Corp. now owns 157,116 shares of the company’s stock valued at $7,999,000 after buying an additional 70,403 shares during the period. Teacher Retirement System of Texas boosted its holdings in shares of Ralliant by 6.9% during the 4th quarter. Teacher Retirement System of Texas now owns 570,878 shares of the company’s stock worth $29,063,000 after buying an additional 36,800 shares in the last quarter. Alpha Omega Wealth Management LLC boosted its holdings in shares of Ralliant by 615.8% during the 4th quarter. Alpha Omega Wealth Management LLC now owns 40,291 shares of the company’s stock worth $2,051,000 after buying an additional 34,662 shares in the last quarter. Rokos Capital Management LLP acquired a new stake in shares of Ralliant during the 1st quarter worth approximately $42,022,000. Finally, Walleye Capital LLC acquired a new stake in shares of Ralliant during the 1st quarter worth approximately $4,525,000.

About Ralliant

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.